Christopher Warlick, MD, PhD

Associate Professor, Department of Urology

Christopher Warlick

Contact Info

Administrative Assistant Name
Casey Pratt

Administrative Phone

Administrative Email

Administrative Fax Number

Additional Locations


Associate Professor, Department of Urology

Interim Department Head, Department of Urology

Urologic Surgeon

University of Minnesota (M.D., Ph.D.)

Johns Hopkins Medical Institutions, Baltimore MD (Urology)


Dr. Christopher Warlick currently serves as the Interim Department Head for the Department of Urology and is an Associate Professor who treats several urologic cancers, with an emphasis on prostate cancer. Dr. Warlick has a busy prostate cancer practice and is a nationally recognized leader on Active Surveillance for low risk prostate cancer, while performing robotic-assisted laparoscopic radical prostatectomies for men requiring definitive therapy. Dr. Warlick has ongoing research focusing on the use of MR imaging in prostate cancer, the development of novel tests to help determine early signs of disease progression, and on programs to increase the use of shared decision making around PSA screening and prostate cancer treatment decision making.


  • Urologic oncology
  • Prostate cancer
  • Expectant management for prostate cancer
  • Kidney cancer
  • Bladder cancer



  • Sathianathen NJ, Warlick CA, Weight CJ, Ordonez MA, Spilseth B, Metzger GJ, Murugan P, Konety BR. A clinical prediction tool to determine the need for the concurrent systematic sampling at the time of magnetic resonance imaging-guided biopsy. BJU Int. 2019 Apr.
  • Warlick CA, Futterer J, Maruf M, George AK, Rastinehad AR, Pinto PA, Bosaily AE, Villers A, Moore CM, Mendhiratta N, Taneja SS, Ukimura O, Konety BR. Beyond transrectal ultrasound-guided prostate biopsies: available techniques and approaches. World J Urol. 2019 Mar.
  • Sathianathen NJ, Warlick CA, Soubra A, Balaji P, Metzger GJ, Spilseth B, Murugan P, Ordonez M, Weight CJ, Konety BR. Difference in MRI-guided biopsy cancer detection rates between individual clinicians. Urol Oncol. 2019 Feb 21.
  • Rogers CR, Rovito MJ, Hussein M, Obidike OJ, Pratt R, Alexander M, Berge JM, Dall'Era M, Nix JW, Warlick CA. Attitudes Toward Genomic Testing and Prostate Cancer Research Among Black Men. Am J Prev Med. 2018 Nov.
  • Shapovalova M, Davydova J, Henzler C, Daniel M, Dehm SM, Warlick CA, LeBeau AM. Exploiting the transcriptional specificity of the alpha-methylacyl-CoA racemase AMACR promoter for the molecular imaging of prostate cancer. Oncotarget. 2018 Nov.
  • Sathianathen NJ, Konety BR, Soubra A, Metzger GJ, Spilseth B, Murugan P, Weight CJ, Ordonez MA, Warlick CA. Which scores need a core? An evaluation of MR-targeted biopsy yield by PIRADS score across different biopsy indications
  • Sathianathen NJ, Warlick CA. The Use of Magnetic Resonance Imaging in the Prostate Cancer Primary Diagnostic Pathway: Is It Ready for Primetime? World J Mens Health. 2018 Sep.
  • Jiang S, Narayan V, Warlick CA. Racial disparities and considerations for active surveillance of prostate cancer. Transl Androl Urol. 2018 Apr.
  • Narayan V, Jiang S, Warlick CA. Early Stage Cancer in Older Adults: Prostate-Avoiding Overtreatment and Undertreatment. Cancer J. 2017 Jul/Aug.
  • Narayan VM, Konety BR, Warlick CA. Novel biomarkers for prostate cancer: An evidence-based review for use in clinical practice. Int J Urol. 2017 May.



  • Urologic oncology, Prostate cancer, Expectant management for prostate cancer, Kidney cancer, Bladder cancer, Genitourinary cancer